Moffitt Cancer Center | Strategic Alliance Partners

January 27, 2024

Focus on methods for preventing graft-versus-host disease (GvHD) following allo-HSCT, such as pharmacologic immune suppression and stem cell graft manipulation techniques.

January 27, 2024

Summarize ongoing and recently completed clinical trials related to allo-HSCT and associated therapies.

January 26, 2024

Faculty provide insights into the selection of BTK inhibitors, emphasizing the role of efficacy, toxicity, and quality of life data in treatment decisions, and exploring the impact of MAIC data.

January 26, 2024

Panel experts examine considerations for BTKi-based strategies in R/R CLL, highlighting pivotal findings from head-to-head trials, including acalabrutinib vs ibrutinib in ELEVATE-RR and zanubrutinib vs ibrutinib in ALPINE, covering safety, quality of life, and extended follow-up data.

January 25, 2024

Francesco Di Meo, PhD, discusses the potential efficacy of CAR T-cells targeting the immunoreceptor LILRB4 in multiple myeloma.

January 23, 2024

Peter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.

January 23, 2024

Jennifer Crombie, MD, discusses how to choose CAR T-cells as third-line and beyond therapy for FL.

January 22, 2024

Richard Kim, MD, discusses data from a real-world investigation of long-term responses with regorafenib in patients with metastatic colorectal cancer.

January 20, 2024

Nicole D. Vincelette, PhD, discusses the role of MYC expression in a subgroup of triple-negative myeloproliferative neoplasms.

January 19, 2024

Analyze risks and complications associated with allo-HSCT, including graft-versus-host disease, infections, relapse, and regimen-related toxicities.

January 19, 2024

This presentation will detail the supportive therapies and interventions provided to patients before, during, and after undergoing allo-HSCT. The speaker will also discuss management of treatment side effects and comorbidities to optimize patient outcomes.

January 19, 2024

Delve into the pre-transplant conditioning regimens such as chemotherapy and radiation used to prepare and immunosuppress patients to prevent graft rejection prior to allogeneic hematopoietic stem cell transplantation.

January 19, 2024

Faculty share insights into the overall strategy for managing relapsed/refractory CLL following first-line therapy with venetoclax-based regimens and BTK inhibitors, discussing strategy variations based on prior first-line treatments.

January 19, 2024

Experts explore the role of BTKi-based combination therapy in the front-line treatment of CLL, focusing on patient considerations and referencing key data from CAPTIVATE, FLAIR, MAJIC, and SEQUOIA (Arm D).

January 18, 2024

Iman Imanirad, MD, medical oncologist, gastrointestinal oncology, Moffitt Cancer Center, discusses the management of toxicities associated with standard-of-care encorafenib plus cetuximab for patients with previously treated microsatellite stable BRAF V600E metastatic colorectal cancer.

January 17, 2024

Richard Kim, MD, discusses ongoing and planned research at Moffitt Cancer Center in patients with hepatocellular carcinoma.

January 16, 2024

A panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.

January 16, 2024

Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.

January 12, 2024

Richard Kim, MD, discusses selecting between frontline immunotherapy-based regimens in patients with hepatocellular carcinoma.

January 12, 2024

Javier Pinilla, MD, PhD, provides a brief overview of the changing CLL treatment landscape, discussing the influence of off-target adverse events and the development of treatment resistance on the evolution of BTK inhibitor therapy.